1. HBW Insight
  2. >>Ingredients & Safety

Interested In Using CBD Or Probiotics In Cosmetics? Ask Yourself Why – FDA’s Linda Katz

 
• By Ryan Nelson

The answer to the ‘why’ question can help clarify whether a company is marketing a cosmetic or an unapproved drug, FDA’s cosmetics office director advised attendees at ICMAD’s 38th annual regulatory workshop in New York.

Slow-Down Sign_147945794_1200.jpg

The US Food and Drug Administration has yet to take a firm position on either CBD or probiotics in cosmetics, but advises companies to take a cautious approach to the ingredients’ use.

Presenting May 9 at the Independent Cosmetic Manufacturers and Distributors’ 38th annual regulatory workshop in New York, Linda Katz, director...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

German Quaternary Wastewater Treatment Cost Estimates ‘Not Realistic’

 
• By David Ridley

Updating wastewater treatment facilities in Germany will cost almost three times more than the German Association of Local Public Utilities (VKU) has predicted, according to a Pharma Deutschland analysis.

GSCF: ‘No One Size Fits All’ Solution To Tricky Sustainable Blister Pack Challenge

 
• By David Ridley

A series of research papers recently published by the Global Self-Care Federation indicate that industry will need to be pragmatic about alternatives to PVC in medicine blister packs.

EFSA: ‘A Dose Of Estragole Without A Harmful Effect Cannot Be Established’

 
• By David Ridley

Dietary supplements containing estragole may have to be removed from the European Union market due to carcinogenic risk, according to a draft scientific opinion from EFSA that is currently out for consultation.

Urban Wastewater Directive: AESGP Requests Intervention In EFPIA’s Legal Action

 
• By David Ridley

AESGP has formally submitted a request to the General Court of the European Union to intervene in the European Federation of Pharmaceutical Industries and Association’s legal action against the revised EU Urban Wastewater Directive.

More from HBW Insight

Lauder Says Tariffs Will Shave $100M from FY2026 Profits, As ‘Beauty Reimagined’ Lifts Topline

 
• By Eileen Francis

Estee Lauder says tariffs will hit its bottom line by $100m in fiscal year 2026, as it continues to work toward mitigation strategies. For the full fiscal year 2026, ELC estimates its sales will be in line with or ahead of prestige beauty in key markets, with reported sales in the range of 2%-5%.

Advocate For 7-OH Sees No ‘Public Health Emergency’ Or ‘Sort Of Signal’ For Scheduling

 
• By Malcolm Spicer

Holistic Alternative Recovery Trust says FDA should review data and other information available about the safety of all kratom extracts before it moves ahead on its proposal to recommend Schedule I controlled substance for 7-OH.

Kratom Industry Argues FDA Scheduling Plan Shows 7-OH At Root Of Botanical’s Regulatory Rot

 
• By Malcolm Spicer

Supporters of planned FDA action to recommend DEA schedule 7-OH include Global Kratom Coalition and Regulatory Service International consultancy firm. AHPA also supports FDA decision but says marketers of kratom extract mitragynine likely aren’t out of the weeds as far as questions about safety.